IDH1 and central nervous system cancer: In the INDIGO trial, the dual isocitrate dehydrogenase 1/2 (IDH1/2) inhibitor vorasidenib demonstrated superior efficacy over placebo in prolonging magnetic resonance imaging (MRI)‐based progression‐free survival and time to next intervention in patients with IDH1/2‐mutant grade 2 glioma after surgery.1